Surge in prevalence of prostate-related diseases such as benign prostatic hyperplasia (BPH) and prostate cancer, mainly driven by aging populations is fueling the prostate health market size.
Furthermore, rise in awareness of prostate health and the benefits of early diagnosis and treatment cumulatively increases the demand for healthcare products and services related to the same.
Continued evolution of diagnostic tools and specific technological advancements in treatments are key market catalysts. Advancement of precision medicine and personalized treatment options developed around an individual patient's profile, resulting in the enhancement of outcome efficacy and patient benefit are likely to bolster the prostate health industry growth.
Telemedicine and digital health platforms are revolutionizing post-care management for patients and follow-up care, as they allow easy access to health services and continuous monitoring.
The prostate health market is experiencing significant growth as more individuals undergo regular health screenings, and the demand for diagnostic and therapeutic solutions continues to expand.
Preventive healthcare measures with more intensive regular screening and early detection programs all work proactively to decrease the rate and severity of prostate disorders, consequently reducing medical costs and offering patients a better quality of life.
Investment in research and development has also increased expeditiously, with pharmaceutical companies and medical device manufacturing companies devoting huge resources to come up with treatments and diagnostic methods.
This investment is bound to lead to a regular flow of new and innovative products that will better address medical needs and therapeutically improve treatment options.
The market is strongly driven by technological advancements. Innovations in several diagnostic tools, including improvements in imaging techniques and biomarker tests, increases the accuracy of early detection of prostate conditions. Moving treatment toward less invasive surgeries and new pharmaceuticals is likely to improve results while reducing recovery times.
| Attribute | Detail |
|---|---|
| Drivers |
|
As the population ages globally, the incidence of age-related diseases, which include prostate diseases also increases. According to the WHO, the world's population over the age of 60 years is projected to reach 2.1 billion by 2050 compared to 1 billion in 2020.
The pathological processes that most commonly affects the prostate gland in older men are benign prostatic hyperplasia (BPH) and prostate cancer.
The incidence of BPH increases markedly with age and is estimated to affect approximately 50% of men between 51 and 60 years of age and up to 90% of men over 80. Likewise, the risk of prostate cancer also increases with age, and the majority of cases are generally diagnosed in men over 65.
It is this demographic transition itself that imposes the pressing demand for medical interventions, screening programs, and chronic management of prostate care.
Funding agencies and researchers have geared the public health agenda toward the aging population; this has subsequently led to surge in funding and research on age-related diseases for most healthcare systems across the globe.
Pharmaceutical companies and medical device manufacturers are developing products specifically targeted at this demand, such as BPH drugs and advanced diagnostic tools for early cancer detection.
Thus, the increase in number of elderly patients with prostate diseases that builds strong demand for innovative and effective solutions is significantly fostering prostate health market development.
New technology in medical imaging, biomarkers, and minimally invasive surgical techniques has improved the detection and treatment of prostate conditions significantly.
For example, the use of multiparametric MRI in the early detection and proper diagnosis of prostate cancer is expected to increase the differentiation between aggressive and indolent tumors. In this way, more targeted biopsies are possible, reducing the number of invasive procedures and resulting in substantial improvements in diagnostic accuracy.
Furthermore, minimally invasive surgery has evolved with the development of robotic-assisted prostatectomy for better outcomes. The procedures are more precise, cause less blood loss, and have much quicker recovery rates than traditional open surgery.
Promising therapeutic methods include new radiation therapies, such as proton beam therapy and high-intensity focused ultrasound, which are extremely effective for treatment and have lower side effects.
Newly developed drugs and targeted therapies open new doors for treatment, primarily for patients who have advanced prostate cancer. All these factors are expected to offer lucrative prostate health market opportunities.
Adenoviruses are used in new therapies, including gene therapy and viral vector vaccines, which target cancer cells more effectively and simultaneously activate the immune system to combat the disease. These therapies have promising outcomes, including decreased side effects and increased efficacy compared to conventional treatments.
Based on disease type, the prostate health market is segmented into prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer. The market is dominated by prostate cancer that includes adenocarcinoma, transitional cell carcinoma, squamous cell carcinoma, and small cell prostate cancer, which are rampant, mostly in men.
As the most commonly diagnosed cancer in men, the demand for effective diagnostic and treatment options for prostate cancer has surged, resulting in significant advances in research and clinical practice of medicine, enabling better patient outcomes.
Within this, considerable attention is currently being devoted to adenovirus-based therapies, and they enjoy substantial market shares.
As per the prostate health industry report, based on treatment, the hormone therapy segment dominated the market in 2023. Hormone therapy is an effective first-line treatment approach for cancer.
The therapy works by reducing or blocking the body's production of androgens, which are hormones that can promote the growth of cancer cells.
The major stimulus for growth in the hormone therapy market is the upsurge in patient outcomes due to newer advancements. New medications, such as androgen receptor inhibitors, have led to more efficacious and targeted management of the disease.
Such innovation increases treatment efficacy and decreases the side effects as opposed to traditional therapies currently adopted; this makes them attractive to both patients and healthcare providers.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
According to the prostate health market analysis, North America held major share in 2023. Growth in target population, high incidence of BPH, prostate cancer, and prostatitis, and strong presence of medical device manufacturers are driving market dynamics in the region.
Favorable reimbursement policies, growing healthcare infrastructure, research and development investments, and product launches also support market expansion. Advanced healthcare infrastructure and comprehensive access to modern medical technologies lead to a further rise in prostate health market share of North America.
Regular health screenings and early detection programs are well embedded into the healthcare system in the region to facilitate early diagnosis and effective management of prostate conditions. Comprehensive insurance coverage also fuels market progress.
The prostate health market is fragmented with the presence of a large number of players. Abbott Laboratories, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb (BMS), Eli Lilly and Company, Ferring Pharmaceuticals, GSK PLC., Johnson & Johnson, Merck and Co. Inc., Pfizer Inc., and Siemens Healthineers AG are the prominent prostate health industry players.
Key players have been have been profiled in the prostate health market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Size in 2023 | US$ 31.9 Bn |
| Forecast Value in 2034 | More than US$ 83.8 Bn |
| CAGR | 9.2% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 31.9 Bn in 2023
It is projected to grow at a CAGR of 9.2% from 2024 to 2034
In terms of disease type, the prostate cancer segment accounted for prominent share in 2023
North America is anticipated to account for leading share during the forecast period
Abbott Laboratories, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb (BMS), Eli Lilly and Company, Ferring Pharmaceuticals, GSK PLC., Johnson & Johnson, Merck and Co. Inc., Pfizer Inc., and Siemens Healthineers AG
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Prostate Health Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Prostate Health Market Analysis and Forecast, 2020-2034
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Regulatory Scenario by region/globally
5.2. Key Industry Events (Product Launches, Collaborations and Partnerships, Acquisitions, Approvals etc.)
5.3. Pipeline Analysis
5.4. Reimbursement Scenario by Key Countries
5.5. Disease Diagnosis of Prostate Diseases (Prostatitis, Benign Prostate Hyperplasia, Prostate Cancer, etc.)
5.6. Brand Analysis
5.7. Pricing Analysis
5.8. Covid-19 Pandemic Impact on Industry
6. Global Prostate Health Market Analysis and Forecast, by Disease Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease Type, 2020-2034
6.3.1. Prostatitis
6.3.2. Benign Prostatic Hyperplasia (BPH)
6.3.3. Prostate Cancer
6.3.3.1. Adenocarcinoma
6.3.3.2. Transitional Cell Carcinoma
6.3.3.3. Squamous Cell Carcinoma
6.3.3.4. Small Cell Prostate Cancer
6.4. Market Attractiveness Analysis, by Disease Type
7. Global Prostate Health Market Analysis and Forecast, by Treatment
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Treatment, 2020-2034
7.3.1. Chemotherapy
7.3.2. Hormone Therapy
7.3.3. Immunotherapy
7.4. Market Attractiveness Analysis, by Treatment
8. Global Prostate Health Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2020-2034
8.3.1. Oral
8.3.2. Parenteral
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Prostate Health Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2020-2034
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global Prostate Health Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Region
11. North America Prostate Health Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Disease Type, 2020-2034
11.2.1. Prostatitis
11.2.2. Benign Prostatic Hyperplasia (BPH)
11.2.3. Prostate Cancer
11.2.3.1. Adenocarcinoma
11.2.3.2. Transitional Cell Carcinoma
11.2.3.3. Squamous Cell Carcinoma
11.2.3.4. Small Cell Prostate Cancer
11.3. Market Value Forecast, by Treatment, 2020-2034
11.3.1. Chemotherapy
11.3.2. Hormone Therapy
11.3.3. Immunotherapy
11.4. Market Value Forecast, by Route of Administration, 2020-2034
11.4.1. Oral
11.4.2. Parenteral
11.5. Market Value Forecast, by Distribution Channel, 2020-2034
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Disease Type
11.7.2. By Treatment
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Prostate Health Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Disease Type, 2020-2034
12.2.1. Prostatitis
12.2.2. Benign Prostatic Hyperplasia (BPH)
12.2.3. Prostate Cancer
12.2.3.1. Adenocarcinoma
12.2.3.2. Transitional Cell Carcinoma
12.2.3.3. Squamous Cell Carcinoma
12.2.3.4. Small Cell Prostate Cancer
12.3. Market Value Forecast, by Treatment, 2020-2034
12.3.1. Chemotherapy
12.3.2. Hormone Therapy
12.3.3. Immunotherapy
12.4. Market Value Forecast, by Route of Administration, 2020-2034
12.4.1. Oral
12.4.2. Parenteral
12.5. Market Value Forecast, by Distribution Channel, 2020-2034
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. Germany
12.6.2. UK
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Disease Type
12.7.2. By Treatment
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Prostate Health Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Disease Type, 2020-2034
13.2.1. Prostatitis
13.2.2. Benign prostatic hyperplasia (BPH)
13.2.3. Prostate Cancer
13.2.3.1. Adenocarcinoma
13.2.3.2. Transitional Cell Carcinoma
13.2.3.3. Squamous Cell Carcinoma
13.2.3.4. Small Cell Prostate Cancer
13.3. Market Value Forecast, by Treatment, 2020-2034
13.3.1. Chemotherapy
13.3.2. Hormone Therapy
13.3.3. Immunotherapy
13.4. Market Value Forecast, by Route of Administration, 2020-2034
13.4.1. Oral
13.4.2. Parenteral
13.5. Market Value Forecast, by Distribution Channel, 2020-2034
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Disease Type
13.7.2. By Treatment
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Prostate Health Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Disease Type, 2020-2034
14.2.1. Prostatitis
14.2.2. Benign prostatic hyperplasia (BPH)
14.2.3. Prostate Cancer
14.2.3.1. Adenocarcinoma
14.2.3.2. Transitional Cell Carcinoma
14.2.3.3. Squamous Cell Carcinoma
14.2.3.4. Small Cell Prostate Cancer
14.3. Market Value Forecast, by Treatment, 2020-2034
14.3.1. Chemotherapy
14.3.2. Hormone Therapy
14.3.3. Immunotherapy
14.4. Market Value Forecast, by Route of Administration, 2020-2034
14.4.1. Oral
14.4.2. Parenteral
14.5. Market Value Forecast, by Distribution Channel, 2020-2034
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Disease Type
14.7.2. By Treatment
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Prostate Health Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Disease Type, 2020-2034
15.2.1. Prostatitis
15.2.2. Benign prostatic hyperplasia (BPH)
15.2.3. Prostate Cancer
15.2.3.1. Adenocarcinoma
15.2.3.2. Transitional Cell Carcinoma
15.2.3.3. Squamous Cell Carcinoma
15.2.3.4. Small Cell Prostate Cancer
15.3. Market Value Forecast, by Treatment, 2020-2034
15.3.1. Chemotherapy
15.3.2. Hormone Therapy
15.3.3. Immunotherapy
15.4. Market Value Forecast, by Route of Administration, 2020-2034
15.4.1. Oral
15.4.2. Parenteral
15.5. Market Value Forecast, by Distribution Channel, 2020-2034
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Market Value Forecast, by Country/Sub-region, 2020-2034
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Disease Type
15.7.2. By Treatment
15.7.3. By Route of Administration
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of companies)
16.2. Market Share Analysis By Company (2023)
16.3. Company Profiles
16.3.1. Abbott Laboratories
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Amgen Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Astellas Pharma Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. AstraZeneca PLC
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Bayer AG
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Bristol-Myers Squibb (BMS)
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Eli Lilly and Company
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Ferring Pharmaceuticals
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. GSK PLC.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Johnson & Johnson
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Merck and Co. Inc.
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. Pfizer Inc.
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. Financial Overview
16.3.12.4. SWOT Analysis
16.3.12.5. Strategic Overview
16.3.13. Siemens Healthineers AG
16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.13.2. Product Portfolio
16.3.13.3. Financial Overview
16.3.13.4. SWOT Analysis
16.3.13.5. Strategic Overview
List of Tables
Table 01: Global Prostate Health Market Value (US$ Mn) Forecast, by Disease Type, 2020-2034
Table 02: Global Prostate Health Market Value (US$ Mn) Forecast, by Prostate cancer, 2020-2034
Table 03: Global Prostate Health Market Value (US$ Mn) Forecast, by Treatment, 2020-2034
Table 04: Global Prostate Health Market Value (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 05: Global Prostate Health Market Value (US$ Mn) Forecast, by Region, 2020-2034
Table 06: North America Prostate Health Market Value (US$ Mn) Forecast, by Country, 2020-2034
Table 07: North America Prostate Health Market Value (US$ Mn) Forecast, by Disease Type, 2020-2034
Table 08: North America Prostate Health Market Value (US$ Mn) Forecast, by Prostate Cancer, 2020-2034
Table 09: North America Prostate Health Market Value (US$ Mn) Forecast, by Treatment, 2020-2034
Table 10: North America Prostate Health Market Value (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 11: Europe Prostate Health Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 12: Europe Prostate Health Market Value (US$ Mn) Forecast, by Disease Type, 2020-2034
Table 13: Europe Prostate Health Market Value (US$ Mn) Forecast, by Prostate Cancer, 2020-2034
Table 14: Europe Prostate Health Market Value (US$ Mn) Forecast, by Treatment, 2020-2034
Table 15: Europe Prostate Health Market Value (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 16: Asia Pacific Prostate Health Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 17: Asia Pacific Prostate Health Market Value (US$ Mn) Forecast, by Disease Type, 2020-2034
Table 18: Asia Pacific Prostate Health Market Value (US$ Mn) Forecast, by Prostate Cancer, 2020-2034
Table 19: Asia Pacific Prostate Health Market Value (US$ Mn) Forecast, by Treatment, 2020-2034
Table 20: Asia Pacific Prostate Health Market Value (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 21: Latin America Prostate Health Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Latin America Prostate Health Market Value (US$ Mn) Forecast, by Disease Type, 2020-2034
Table 23: Latin America Prostate Health Market Value (US$ Mn) Forecast, by Prostate Cancer, 2020-2034
Table 24: Latin America Prostate Health Market Value (US$ Mn) Forecast, by Treatment, 2020-2034
Table 25: Latin America Prostate Health Market Value (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 26: Middle East & Africa Prostate Health Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 27: Middle East & Africa Prostate Health Market Value (US$ Mn) Forecast, by Disease Type, 2020-2034
Table 28: Middle East & Africa Prostate Health Market Value (US$ Mn) Forecast, by Prostate Cancer, 2020-2034
Table 29: Middle East & Africa Prostate Health Market Value (US$ Mn) Forecast, by Treatment, 2020-2034
Table 30: Middle East & Africa Prostate Health Market Value (US$ Mn) Forecast, by Distribution Channel, 2020-2034
List of Figures
Figure 01: Global Prostate Health Market Value (US$ Mn) Forecast, 2020-2034
Figure 02: Global Prostate Health Market Value Share, by Disease Type, 2023
Figure 03: Global Prostate Health Market Value Share, by Treatment, 2023
Figure 04: Global Prostate Health Market Value Share, by Route of Administration, 2023
Figure 05: Global Prostate Health Market Value Share, by Distribution Channel, 2023
Figure 06: Global Prostate Health Market Value Share, by Region, 2023
Figure 07: Global Prostate Health Market Value (US$ Mn) Share Analysis, by Disease Type, 2023 and 2034
Figure 08: Global Prostate Health Market Share Analysis, by Disease Type, 2023
Figure 09: Global Prostate Health Market Share Analysis, by Disease Type, 2034
Figure 10: Global Prostate Health Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 11: Global Prostate Health Market Value (US$ Mn), by Prostatitis, 2020-2034
Figure 12: Global Prostate Health Market Value Share Analysis, by Prostatitis, 2023 and 2034
Figure 13: Global Prostate Health Market Value (US$ Mn), by Benign prostatic hyperplasia (BPH), 2020-2034
Figure 14: Global Prostate Health Market Value Share Analysis, by Benign prostatic hyperplasia (BPH), 2023 and 2034
Figure 15: Global Prostate Health Market Value (US$ Mn), by Prostate cancer, 2020-2034
Figure 16: Global Prostate Health Market Value Share Analysis, by Prostate cancer, 2023 and 2034
Figure 17: Global Prostate Health Market Value (US$ Mn) Share Analysis, by Treatment, 2023 and 2034
Figure 18: Global Prostate Health Market Share Analysis, by Treatment, 2023
Figure 19: Global Prostate Health Market Share Analysis, by Treatment, 2034
Figure 20: Global Prostate Health Market Attractiveness Analysis, by Treatment, 2024-2034
Figure 21: Global Prostate Health Market Value (US$ Mn), by Chemotherapy, 2020-2034
Figure 22: Global Prostate Health Market Value Share Analysis, by Chemotherapy, 2023 and 2034
Figure 23: Global Prostate Health Market Value (US$ Mn), by Hormone Therapy, 2020-2034
Figure 24: Global Prostate Health Market Value Share Analysis, by Hormone Therapy, 2023 and 2034
Figure 25: Global Prostate Health Market Value (US$ Mn), by Immunotherapy, 2020-2034
Figure 26: Global Prostate Health Market Value Share Analysis, by Immunotherapy, 2023 and 2034
Figure 27: Global Prostate Health Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2023 and 2034
Figure 28: Global Prostate Health Market Share Analysis, by Distribution Channel, 2023
Figure 29: Global Prostate Health Market Share Analysis, by Distribution Channel, 2034
Figure 30: Global Prostate Health Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 31: Global Prostate Health Market Value (US$ Mn), by Hospital Pharmacies, 2020-2034
Figure 32: Global Prostate Health Market Value Share Analysis, by Hospital Pharmacies, 2023 and 2034
Figure 33: Global Prostate Health Market Value (US$ Mn), by Retail Pharmacies, 2020-2034
Figure 34: Global Prostate Health Market Value Share Analysis, by Retail Pharmacies, 2023 and 2034
Figure 35: Global Prostate Health Market Value (US$ Mn), by Online Pharmacies, 2020-2034
Figure 36: Global Prostate Health Market Value Share Analysis, by Online Pharmacies, 2023 and 2034
Figure 37: Global Prostate Health Market Value Share Analysis, by Region, 2023 and 2034
Figure 38: Global Prostate Health Market Share Analysis, by Region, 2023
Figure 39: Global Prostate Health Market Share Analysis, by Region, 2034
Figure 40: Global Prostate Health Market Attractiveness Analysis, by Region, 2024-2034
Figure 41: North America Prostate Health Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 42: North America Prostate Health Market Value Share Analysis, by Country, 2023 and 2034
Figure 43: North America Prostate Health Market Attractiveness Analysis, by Country, 2024-2034
Figure 44: North America Prostate Health Market Value (US$ Mn) Share Analysis, by Disease Type, 2023 and 2034
Figure 45: North America Prostate Health Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 46: North America Prostate Health Market Value (US$ Mn) Share Analysis, by Treatment, 2023 and 2034
Figure 47: North America Prostate Health Market Attractiveness Analysis, by Treatment, 2024-2034
Figure 48: North America Prostate Health Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2023 and 2034
Figure 49: North America Prostate Health Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 50: Europe Prostate Health Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 51: Europe Prostate Health Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 52: Europe Prostate Health Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 53: Europe Prostate Health Market Value (US$ Mn) Share Analysis, by Disease Type, 2023 and 2034
Figure 54: Europe Prostate Health Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 55: Europe Prostate Health Market Value (US$ Mn) Share Analysis, by Treatment, 2023 and 2034
Figure 56: Europe Prostate Health Market Attractiveness Analysis, by Treatment, 2024-2034
Figure 57: Europe Prostate Health Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2023 and 2034
Figure 58: Europe Prostate Health Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 59: Asia Pacific Prostate Health Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 60: Asia Pacific Prostate Health Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 61: Asia Pacific Prostate Health Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 62: Asia Pacific Prostate Health Market Value (US$ Mn) Share Analysis, by Disease Type, 2023 and 2034
Figure 63: Asia Pacific Prostate Health Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 64: Asia Pacific Prostate Health Market Value (US$ Mn) Share Analysis, by Treatment, 2023 and 2034
Figure 65: Asia Pacific Prostate Health Market Attractiveness Analysis, by Treatment, 2024-2034
Figure 66: Asia Pacific Prostate Health Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2023 and 2034
Figure 67: Asia Pacific Prostate Health Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 68: Latin America Prostate Health Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 69: Latin America Prostate Health Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 70: Latin America Prostate Health Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 71: Latin America Prostate Health Market Value (US$ Mn) Share Analysis, by Disease Type, 2023 and 2034
Figure 72: Latin America Prostate Health Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 73: Latin America Prostate Health Market Value (US$ Mn) Share Analysis, by Treatment, 2023 and 2034
Figure 74: Latin America Prostate Health Market Attractiveness Analysis, by Treatment, 2024-2034
Figure 75: Latin America Prostate Health Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2023 and 2034
Figure 76: Latin America Prostate Health Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 77: Middle East & Africa Prostate Health Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 78: Middle East & Africa Prostate Health Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 79: Middle East & Africa Prostate Health Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 80: Middle East & Africa Prostate Health Market Value (US$ Mn) Share Analysis, by Disease Type, 2023 and 2034
Figure 81: Middle East & Africa Prostate Health Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 82: Middle East & Africa Prostate Health Market Value (US$ Mn) Share Analysis, by Treatment, 2023 and 2034
Figure 83: Middle East & Africa Prostate Health Market Attractiveness Analysis, by Treatment, 2024-2034
Figure 84: Middle East & Africa Prostate Health Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2023 and 2034
Figure 85: Middle East & Africa Prostate Health Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Prostate Health Market
